Quick Answer
Karyopharm Therapeutics Inc. reported Research And Development Expense of $125.62 million for the year ending 2025.
- Karyopharm Therapeutics Inc. showed a decrease of -12.3% in Research And Development Expense from 2024 to 2025.
- This data is from Karyopharm Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: $4.97 million | Q2 2013: $6.06 million | Q3 2013: $7.74 million | Q1 2014: $10.98 million | Q2 2014: $13.16 million | Q3 2014: $15.95 million | Q1 2015: $20.75 million | Q2 2015: $27.01 million | Q3 2015: $25.92 million | Q1 2016: $21.80 million | Q2 2016: $24.58 million | Q3 2016: $19.89 million | Q1 2017: $24.08 million | Q2 2017: $23.12 million | Q3 2017: $25.24 million | Q1 2018: $41.32 million | Q2 2018: $44.73 million | Q3 2018: $36.43 million | Q1 2019: $37.97 million | Q2 2019: $26.52 million | Q3 2019: $26.27 million | Q1 2020: $34.00 million | Q2 2020: $42.59 million | Q3 2020: $37.04 million | Q1 2021: $37.05 million | Q2 2021: $33.98 million | Q3 2021: $45.81 million | Q1 2022: $42.06 million | Q2 2022: $44.31 million | Q3 2022: $31.36 million | Q1 2023: $32.34 million | Q2 2023: $31.48 million | Q3 2023: $35.55 million | Q1 2024: $35.43 million | Q2 2024: $38.37 million | Q3 2024: $36.13 million | Q1 2025: $34.62 million | Q2 2025: $32.79 million | Q3 2025: $30.54 million.
- Over the full 15 years of available data (2011 to 2025), Karyopharm Therapeutics Inc.'s Research And Development Expense has grown by 1,356.8%.
- Historical annual values: Fiscal year 2025: $125.62 million | Fiscal year 2024: $143.23 million | Fiscal year 2023: $138.75 million | Fiscal year 2022: $148.66 million | Fiscal year 2021: $160.84 million | Fiscal year 2020: $150.81 million | Fiscal year 2019: $122.34 million | Fiscal year 2018: $161.37 million | Fiscal year 2017: $107.27 million | Fiscal year 2016: $86.94 million | Fiscal year 2015: $97.74 million | Fiscal year 2014: $60.13 million | Fiscal year 2013: $28.45 million | Fiscal year 2012: $14.10 million | Fiscal year 2011: $8.62 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: